MDGL
MADRIGAL PHARMACEUTICALS, INC.Company Information
- Company Name
- MADRIGAL PHARMACEUTICALS, INC.
- CIK
- CIK0001157601
- Category
- Large accelerated filer
- Ticker: Exchange
- MDGL: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- MDGL
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-08-20
- Last sale
- 2026-09-11
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 105,691
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 23,117,676
- Shares outstanding
- 29,145,271
- Ownership
- 79.32%
Earnings Market Reaction
- Filing date
- 2026-07-30
- Price on filing date
- —
- 1-month reaction
- 4.79%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 293 | 227 | 199 | 296 | 186 | 184 | 100 | 233 | 495 | 623 | 100 | 62 | ||||||
| Restricted Cash | - | - | - | 5 | 5 | 5 | - | 5 | 5 | - | - | - | ||||||
| Restricted Cash Current | 0 | 5 | 5 | - | - | - | 5 | - | - | - | 0 | - | ||||||
| Available For Sale Securities Debt Securities Current | 546 | 586 | 785 | 814 | 611 | 659 | 826 | 766 | 563 | 437 | 534 | 170 | ||||||
| Accounts Receivable Net Current | 192 | 187 | 134 | 113 | 79 | 61 | 54 | 30 | 7 | - | 0 | - | ||||||
| Inventory Net | 99 | 112 | 75 | 69 | 63 | 55 | 34 | 9 | 7 | 1 | 0 | - | ||||||
| Prepaid Expense And Other Assets Current | 69 | 65 | 48 | 49 | 59 | 23 | 14 | 21 | 15 | 14 | 3 | 3 | ||||||
| Assets Current | 1,199 | 1,182 | 1,246 | 1,347 | 1,003 | 988 | 1,033 | 1,064 | 1,092 | 1,074 | 637 | 235 | ||||||
| Property Plant And Equipment Net | 12 | 8 | 1 | 3 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | ||||||
| Finite Lived Intangible Assets Net | 7 | 7 | 7 | 7 | 5 | 5 | 5 | 5 | 5 | 5 | 0 | - | ||||||
| Operating Lease Right Of Use Asset | 6 | 6 | 5 | 5 | 6 | 2 | 2 | 3 | 1 | 2 | 2 | 2 | ||||||
| Other Assets Noncurrent | 21 | 23 | - | - | - | - | - | - | - | - | - | - | ||||||
| Assets | 1,245 | 1,227 | 1,260 | 1,362 | 1,015 | 997 | 1,042 | 1,073 | 1,100 | 1,082 | 641 | 238 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 35 | 61 | 49 | 45 | 38 | 42 | 44 | 46 | 9 | 22 | 28 | 17 | ||||||
| Accrued Liabilities Current | 339 | 276 | 260 | 345 | 157 | 124 | 125 | 131 | 116 | 92 | 90 | 83 | ||||||
| Operating Lease Liability Current | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 374 | 338 | 310 | 391 | 197 | 167 | 169 | 178 | 125 | 114 | 119 | 100 | ||||||
Liabilities Noncurrent | ||||||||||||||||||
| Long Term Debt Noncurrent | 341 | 340 | 340 | 340 | 118 | 118 | 118 | 117 | 117 | 116 | 115 | 115 | ||||||
| Operating Lease Liability Noncurrent | 6 | 5 | 7 | 6 | 5 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Noncurrent | 347 | 346 | 347 | 345 | 123 | 119 | 119 | 118 | 118 | 117 | 117 | 116 | ||||||
| Liabilities | 721 | 684 | 657 | 737 | 319 | 286 | 288 | 296 | 243 | 232 | 235 | 216 | ||||||
Stockholders Equity | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 2,766 | 2,727 | 2,692 | 2,657 | 2,613 | 2,586 | 2,556 | 2,519 | 2,493 | 2,335 | 1,741 | 1,246 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | -0 | -0 | 0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -2,243 | -2,185 | -2,090 | -2,032 | -1,918 | -1,875 | -1,802 | -1,743 | -1,636 | -1,484 | -1,336 | -1,224 | ||||||
| Stockholders Equity | 524 | 543 | 603 | 626 | 696 | 711 | 754 | 777 | 857 | 851 | 405 | 22 | ||||||
| Liabilities And Stockholders Equity | 1,245 | 1,227 | 1,260 | 1,362 | 1,015 | 997 | 1,042 | 1,073 | 1,100 | 1,082 | 641 | 238 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Preferred Stock Shares Issued | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Preferred Stock Shares Outstanding | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | 200 | ||||||
| Common Stock Shares Issued | 23 | 23 | 23 | 23 | 22 | 22 | 22 | 22 | 20 | 20 | 20 | 18 | ||||||
| Shares Outstanding | 23 | 23 | 23 | 23 | 22 | 22 | 22 | 22 | 20 | 20 | 20 | 18 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMADRIGAL PHARMACEUTICALS, INC. (MDGL) — SEC Financial Statements & Analysis
MADRIGAL PHARMACEUTICALS, INC. (MDGL) is a pharmaceutical preparations company, incorporated in DE. MADRIGAL PHARMACEUTICALS, INC. trades on Nasdaq as: MDGL. MADRIGAL PHARMACEUTICALS, INC. (MDGL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30. Based on that filing, MADRIGAL PHARMACEUTICALS, INC. carries a market cap of $15.65B, a P/E ratio of -48.14x, a P/B ratio of 29.88x, a P/S ratio of 12.19x, an enterprise value of $15.70B, and an EV/EBITDA multiple of -48.89x. On profitability, it posts an operating margin of -25.13%, a net margin of -25.32%, a Return on Equity (ROE) of -53.31%, a Return on Assets (ROA) of -28.77%, and a Return on Invested Capital (ROIC) of -52.42%. Per share, it reports EPS of $-11.15, diluted EPS of $-11.15, free cash flow per share of $-7.10, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 149.04% year-over-year, net income growth of 15.32% year-over-year, and EPS growth of 11.71% year-over-year. On the balance sheet, it maintains a current ratio of 3.20x, a quick ratio of 2.76x, working capital of $824.98M, a debt-to-equity ratio of 1.38x, a debt ratio of 0.58, an interest coverage ratio of -10.24x, free cash flow of $-207.06M (TTM), and net debt of $47.91M. Figures sourced from SEC EDGAR.
- Market Cap
- $15.65B
- P/E TTM
- -48.14x
- EPS TTM
- $-11.15
- P/B TTM
- 29.88x
- ROE TTM
- -53.31%
- ROA TTM
- -28.77%
- Debt To Equity
- 1.38x
- Free Cash Flow TTM
- $-207.06M
- Net Revenue TTM Growth 1Y
- 149.04%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is MADRIGAL PHARMACEUTICALS, INC. in?
MADRIGAL PHARMACEUTICALS, INC. (MDGL) operates in the Pharmaceutical Preparations industry.
What exchange does MDGL trade on?
MADRIGAL PHARMACEUTICALS, INC. (MDGL) trades on the Nasdaq.
Where is MADRIGAL PHARMACEUTICALS, INC. incorporated?
MADRIGAL PHARMACEUTICALS, INC. is incorporated in DE.
When was MADRIGAL PHARMACEUTICALS, INC. (MDGL)'s most recent SEC filing?
MADRIGAL PHARMACEUTICALS, INC. (MDGL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-07-30.
What is MDGL's market cap?
MADRIGAL PHARMACEUTICALS, INC. (MDGL) has a market capitalization of $15.65B as of 2026-06-30.
What is MDGL's EPS (earnings per share)?
MADRIGAL PHARMACEUTICALS, INC. (MDGL)'s trailing twelve month EPS is $-11.15 as of 2026-06-30.
What is MDGL's ROE (return on equity)?
MADRIGAL PHARMACEUTICALS, INC. (MDGL)'s trailing twelve month Return on Equity (ROE) is -53.31% as of 2026-06-30.
What is MDGL's ROA (return on assets)?
MADRIGAL PHARMACEUTICALS, INC. (MDGL)'s trailing twelve month Return on Assets (ROA) is -28.77% as of 2026-06-30.
What is MDGL's ROIC (return on invested capital)?
MADRIGAL PHARMACEUTICALS, INC. (MDGL)'s trailing twelve month Return on Invested Capital (ROIC) is -52.42% as of 2026-06-30.
What is MDGL's EV/EBITDA?
MADRIGAL PHARMACEUTICALS, INC. (MDGL)'s trailing twelve month EV/EBITDA is -48.89x as of 2026-06-30.